Kiromic BioPharma, Inc.: Revision history

20 August 2022

• curprev 05:5005:50, 20 August 2022 95.149.241.133 talk 952 bytes +11 No edit summary undo

13 August 2022

• curprev 07:1507:15, 13 August 2022 109.180.50.163 talk 941 bytes +15 No edit summary undo

29 July 2022

• curprev 22:3422:34, 29 July 2022 >Chris 926 bytes +926 Created page with "Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell to target solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; and ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1. It..."